TY - JOUR T1 - A Systematic Review of Clinical Practice Guidelines for Alzheimer's Disease and Strategies for Future Advancements. AU - Tahami Monfared,Amir Abbas, AU - Phan,N T Nhan, AU - Pearson,Isobel, AU - Mauskopf,Josephine, AU - Cho,Min, AU - Zhang,Quanwu, AU - Hampel,Harald, Y1 - 2023/06/01/ PY - 2023/04/20/received PY - 2023/05/17/accepted PY - 2023/6/1/medline PY - 2023/6/1/pubmed PY - 2023/6/1/entrez KW - Alzheimer’s disease KW - Diagnosis KW - Drug therapy KW - Mild cognitive impairment KW - Systematic review SP - 1257 EP - 1284 JF - Neurology and therapy JO - Neurol Ther VL - 12 IS - 4 N2 - INTRODUCTION: Alzheimer's disease (AD) is a disease continuum from pathophysiologic, biomarker and clinical perspectives. With the advent of advanced technologies, diagnosing and managing patients is evolving. METHODS: A systematic literature review (SLR) of practice guidelines for mild cognitive impairment (MCI) and AD dementia was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). This systematic literature review (SLR) aimed to summarize current clinical practice guidelines for screening, testing, diagnosis, treatment and monitoring in the AD continuum. The results of this SLR were used to propose a way forward for practice guidelines given the possible introduction of biomarker-guided technology using blood- or plasma-based assays and disease-modifying treatments (DMTs) targeted for early disease. RESULTS: 53 clinical practice guidelines were identified, 15 of which were published since 2018. Screening for asymptomatic populations was not recommended. Biomarker testing was not included in routine diagnostic practice. There was no consensus on which neurocognitive tests to use to diagnose and monitor MCI or AD dementia. Pharmacologic therapies were not recommended for MCI, while cholinesterase inhibitors and memantine were recommended for AD treatment. DISCUSSION: The pre-2018 and post-2018 practice guidelines share similar recommendations for screening, diagnosis and treatment. However, once DMTs are approved, clinicians will require guidance on the appropriate use of DMTs in a clinical setting. This guidance should include strategies for identifying eligible patients and evaluating the DMT benefit-to-risk profile to facilitate shared decision-making among physicians, patients and care partners. CONCLUSION: Regular evidence-based updates of existing guidelines for the AD continuum are required over the coming decades to integrate rapidly evolving technologic and medical scientific advances and bring emerging approaches for management of early disease into clinical practice. This will pave the way toward biomarker-guided identification and targeted treatment and the realization of precision medicine for AD. SN - 2193-8253 UR - https://www.unboundmedicine.com/medline/citation/37261607/full_citation DB - PRIME DP - Unbound Medicine ER -